INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
SEC 13F/TRIMVerified data

ARK Investment Management LLC sold TXG

13F filer · 10x Genomics, Inc. · 10X Genomics Inc

Side
SELL
Δ value
$65.72M
Shares
1.71M
Price
$38.34
Executed
Not disclosed
Disclosed
Aug 14, 2026

TXG · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
31/ 100 · ELEVATED
Methodology →
  • Transaction type+6 / 20

    TRIM

  • Relative size+12 / 25

    $65.7M quarter-over-quarter change

  • Filing timing0 / 15

    Not applicable — 13F reports quarter-end holdings, execution dates are not disclosed

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering+5 / 15

    1 other actor traded the same direction within 14 days

Other disclosed activity · TXG

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
13
TA
Taich AdamChief Financial Officer
TXG10x Genomics, Inc.
Open-market sale · 10b5-1 plan
SELL

Evidence

Verified data

Read directly from the primary public document; every field below is as reported by the filer.

Source

Document
SEC Form 13F-HR
Publisher
U.S. Securities and Exchange Commission (EDGAR)
Document ID
0001104659-26-096910

Timestamps

Event (reported)
Not reported
Published
Aug 14, 2026
Ingested by INSIDER
Nov 4, 22:39 UTC
Last re-read
Nov 5, 07:36 UTC

Extracted facts

Filer
ARK Investment Management LLC
Role
13F filer
Transaction
TRIM
Asset
10X Genomics Inc
Ticker
TXG
Shares
1.71M
Price per share
$38.34
Value
$65,724,731
Owned after transaction
10.00M shares

What this establishes

ARK Investment Management LLC reported this position change in a quarterly 13F holdings report. 13F shows quarter-end positions only — it does not say when during the quarter shares were bought or sold.

Extraction

Method
13F information table XML
Confidence
1.00
13F filer
ARK Investment Management LLCcik:0001697748
Issuer
10x Genomics, Inc.cik:0001770787

Revision history · 0

No field has changed since this record was first ingested.

Company events

No records

No material filings recorded for this issuer.

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    $77K
    1,206 sh
    Sep 9, 2026
    Sep 11, 2026
    traded Sep 9, 2026
    +2d
    SEC FORM 4

    Evidence

    23
    TA
    Taich AdamChief Financial Officer
    TXG10x Genomics, Inc.
    Open-market sale · 10b5-1 plan
    SELL$2.02M
    31.4K sh
    Sep 9, 2026Sep 11, 2026
    traded Sep 9, 2026
    +2dSEC FORM 4

    Evidence

    16
    TA
    Taich AdamChief Financial Officer
    TXG10x Genomics, Inc.
    Open-market sale · 10b5-1 plan
    SELL$898K
    13.8K sh
    Sep 9, 2026Sep 11, 2026
    traded Sep 9, 2026
    +2dSEC FORM 4

    Evidence

    18
    SS
    Saxonov SergeDirector, Chief Executive Officer
    TXG10x Genomics, Inc.
    Open-market sale · 10b5-1 plan
    SELL$221K
    3,500 sh
    Aug 26, 2026Aug 28, 2026
    traded Aug 26, 2026
    +2dSEC FORM 4

    Evidence

    21
    SS
    Saxonov SergeDirector, Chief Executive Officer
    TXG10x Genomics, Inc.
    Open-market sale · 10b5-1 plan
    SELL$415K
    6,494 sh
    Aug 26, 2026Aug 28, 2026
    traded Aug 26, 2026
    +2dSEC FORM 4

    Evidence

    15
    SS
    Saxonov SergeDirector, Chief Executive Officer
    TXG10x Genomics, Inc.
    Open-market sale · 10b5-1 plan
    SELL$32K
    492 sh
    Aug 26, 2026Aug 28, 2026
    traded Aug 26, 2026
    +2dSEC FORM 4

    Evidence